Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ESTRELLA CLINICAL RESEARCH from Herentals, company number BE0737730926, closed financial year 2025 with a result of € -10,112 after tax. For that financial year ESTRELLA CLINICAL RESEARCH recorded a gross margin of € 7,486 and equity of € -8,112. Compared with financial year 2024, the result moved from € 1,231 to € -10,112. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.
€ -8,112
▼ € 10,112 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,112
▼ still € 1,231 profit in 2024
Profit after tax over the fiscal year.
€ 135
▼ € 30,666 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -10,112.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 39,744
▼ 28% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 41,836
▼ 25% vs 2024
€ 14,632 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1,161
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 647
▼ 90% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 156,285 | € 132,543 | € 22,166 | € 7,486 | ▼ 66% |
| Profit after taxes | € 122,535 | € 97,288 | € 1,231 | € -10,112 | ▼ € 11,343 |
| Equity | € 4,938 | € 36,715 | € 2,000 | € -8,112 | ▼ € 10,112 |
| Total debts | € 201,665 | € 87,173 | € 100,453 | € 49,593 | ▼ 51% |
| Cash | € 43,942 | € 36,442 | € 30,801 | € 135 | ▼ € 30,666 |
| Retained profit | € 2,938 | € 34,715 | € 0 | € -10,112 | |
| Dividend | € 290,000 | € 65,510 | € 35,946 | € 0 | ▼ 100% |
| Bank debt | € 15,204 | € 69,241 | € 55,839 | € 41,836 | ▼ 25% |
| Balance sheet total | € 206,603 | € 123,888 | € 102,453 | € 41,482 | ▼ 60% |
By gross margin, ESTRELLA CLINICAL RESEARCH ranks 10th of 15 companies with main activity “Vervaardiging van farmaceutische grondstoffen” in the province of Antwerp that publish figures (fiscal year 2025).
Key figures of ESTRELLA CLINICAL RESEARCH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about ESTRELLA CLINICAL RESEARCH the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to ESTRELLA CLINICAL RESEARCH?
What happened at ESTRELLA CLINICAL RESEARCH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 10,112 (▼ € 11,343 vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Herentals. KBO
- Pieter VAN LEEMPUTTE became a director. NBB
In short
From € 122,535 profit in 2022 to € 10,112 loss in 2025.
Paid € 65,467 in corporate taxes since 2022.
Best year ever: 2022, with € 122,535 profit.
Paid out € 391,457 in dividends to the owners in total.
Management
Behind ESTRELLA CLINICAL RESEARCH is Pieter VAN LEEMPUTTE.
Directors
According to the 2025 annual accounts
Pieter VAN LEEMPUTTE
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Diamantstraat (HRT) 8 box 305
2200 Herentals
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Antwerp
Same main activity (Vervaardiging van farmaceutische grondstoffen), 20 active companies in the province of Antwerp, largest first.
JNTL Consumer Health (Belgium)
€ 217.6 million revenue · 2025 · Antwerpen
€ 698,777 gross margin · 2026 · Wommelgem
€ 142,659 gross margin · 2025 · Hove
€ 73,970 gross margin · 2025 · Antwerpen
€ 63,117 gross margin · 2025 · Vorselaar
€ 49,670 gross margin · 2025 · Bonheiden
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- VAN LEEMPUTTE Pieter(oprichter) 100%
Details
- Company number
- 0737.730.926
- VAT number
- BE 0737.730.926
- Registered office
- Diamantstraat (HRT) 8 bus 305, 2200 Herentals
- Names & denominations
- ESTRELLA CLINICAL RESEARCH
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 November 2019
- Peppol
- Active · Active since 1 Jun 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van medische beeldvorming en medische laboratoria
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria